See more : Bharat Highways InvIT (BHINVIT.BO) Income Statement Analysis – Financial Results
Complete financial analysis of NanoVibronix, Inc. (NAOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoVibronix, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- CECEP Solar Energy Co.,Ltd. (000591.SZ) Income Statement Analysis – Financial Results
- Blue Blends (India) Limited (BLUEBLENDS.NS) Income Statement Analysis – Financial Results
- B & A Packaging India Limited (BAPACK.BO) Income Statement Analysis – Financial Results
- BYD Company Limited (BYDDF) Income Statement Analysis – Financial Results
- Banaras Beads Limited (BANARBEADS.BO) Income Statement Analysis – Financial Results
NanoVibronix, Inc. (NAOV)
About NanoVibronix, Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.28M | 752.00K | 1.70M | 623.00K | 530.00K | 318.00K | 239.00K | 229.00K | 147.00K | 203.00K | 211.00K | 166.00K | 94.00K |
| Cost of Revenue | 746.00K | 585.00K | 925.00K | 409.00K | 249.00K | 158.00K | 88.00K | 88.00K | 49.00K | 93.00K | 91.00K | 50.00K | 29.00K |
| Gross Profit | 1.54M | 167.00K | 770.00K | 214.00K | 281.00K | 160.00K | 151.00K | 141.00K | 98.00K | 110.00K | 120.00K | 116.00K | 65.00K |
| Gross Profit Ratio | 67.32% | 22.21% | 45.43% | 34.35% | 53.02% | 50.31% | 63.18% | 61.57% | 66.67% | 54.19% | 56.87% | 69.88% | 69.15% |
| Research & Development | 185.00K | 283.00K | 293.00K | 171.00K | 514.00K | 614.00K | 693.00K | 584.00K | 399.00K | 431.00K | 620.00K | 572.00K | 510.00K |
| General & Administrative | 3.92M | 3.93M | 5.06M | 3.77M | 3.82M | 2.64M | 2.08M | 1.36M | 747.00K | 589.00K | 366.00K | 128.00K | 87.00K |
| Selling & Marketing | 864.00K | 965.00K | 1.10M | 993.00K | 1.10M | 1.21M | 465.00K | 514.00K | 377.00K | 301.00K | 244.00K | 190.00K | 150.00K |
| SG&A | 4.79M | 4.90M | 6.16M | 4.76M | 4.92M | 3.85M | 2.55M | 1.87M | 1.12M | 890.00K | 610.00K | 318.00K | 237.00K |
| Other Expenses | 0.00 | 0.00 | -1.63M | 42.00K | -412.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 0.00 | 0.00 |
| Operating Expenses | 4.97M | 5.18M | 6.45M | 4.93M | 5.43M | 4.46M | 3.24M | 2.46M | 1.52M | 1.32M | 1.23M | 890.00K | 747.00K |
| Cost & Expenses | 5.72M | 5.76M | 7.38M | 5.34M | 5.68M | 4.62M | 3.33M | 2.55M | 1.57M | 1.41M | 1.32M | 940.00K | 776.00K |
| Interest Income | 0.00 | 54.00K | 48.00K | 147.00K | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 1.00K | 1.00K |
| Interest Expense | 246.00K | 347.00K | 0.00 | 147.00K | 62.00K | 22.00K | 1.23M | 0.00 | 65.00K | 372.00K | 782.00K | 256.00K | 21.00K |
| Depreciation & Amortization | 1.00K | 1.00K | 2.00K | 2.00K | 4.00K | 6.00K | 5.00K | 7.00K | 9.00K | 9.00K | 10.00K | 9.00K | 10.00K |
| EBITDA | -3.44M | -5.01M | -14.25M | -4.16M | -5.75M | -4.28M | -3.64M | -2.69M | -2.38M | -1.33M | -1.23M | -1.01M | -692.00K |
| EBITDA Ratio | -150.46% | -673.54% | -433.98% | -757.14% | -1,048.87% | -1,344.34% | -1,313.39% | -1,014.85% | -1,238.10% | -1,024.14% | -771.56% | -608.43% | -736.17% |
| Operating Income | -3.44M | -5.01M | -5.68M | -4.72M | -5.15M | -4.30M | -3.09M | -2.32M | -1.42M | -1.21M | -1.11M | -774.00K | -682.00K |
| Operating Income Ratio | -150.50% | -666.49% | -335.28% | -757.46% | -971.89% | -1,353.14% | -1,293.31% | -1,011.35% | -968.71% | -596.55% | -526.07% | -466.27% | -725.53% |
| Total Other Income/Expenses | -246.00K | -401.00K | -8.57M | 408.00K | -660.00K | 22.00K | -1.84M | -398.00K | -1.43M | -1.39M | -844.00K | -501.00K | -41.00K |
| Income Before Tax | -3.68M | -5.41M | -14.25M | -4.31M | -5.81M | -4.28M | -4.93M | -2.71M | -2.86M | -2.60M | -1.95M | -1.28M | -723.00K |
| Income Before Tax Ratio | -161.28% | -719.81% | -840.71% | -691.97% | -1,096.42% | -1,346.23% | -2,061.51% | -1,185.15% | -1,942.86% | -1,279.80% | -926.07% | -768.07% | -769.15% |
| Income Tax Expense | 29.00K | 35.00K | 32.00K | 15.00K | -17.00K | -127.00K | 38.00K | 117.00K | 28.00K | 49.00K | 35.00K | 10.00K | -20.00K |
| Net Income | -3.71M | -5.45M | -14.28M | -4.33M | -5.79M | -4.15M | -4.97M | -2.83M | -2.88M | -2.65M | -1.99M | -1.28M | -723.00K |
| Net Income Ratio | -162.55% | -724.47% | -842.60% | -694.38% | -1,093.21% | -1,306.29% | -2,077.41% | -1,236.24% | -1,961.90% | -1,303.94% | -942.65% | -768.07% | -769.15% |
| EPS | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| EPS Diluted | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| Weighted Avg Shares Out | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
| Weighted Avg Shares Out (Dil) | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a Research Agreement with the Regents of the University of...
NanoVibronix Regains Nasdaq Compliance
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that on November 20, 2023, the Company received official notice from The...
NanoVibronix Issues Letter to Shareholders
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a...
Penny Stocks To Buy Now? 3 to Watch With Big News
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective November 1, its UroShield actuators are eligible for reimbursement on NHS...
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its application for UroShield actuators to be available on NHS Prescription Services'...
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that Dr. Sandra Wilks is scheduled to present the findings from her study...
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into definitive agreements for the purchase and sale of...
Why Is NanoVibronix (NAOV) Up 153% Today?
NanoVibronix (NASDAQ: NAOV ) stock is climbing higher on Wednesday after announcing independent results from a study of its UroShield medical device. The study comes from the University of Southampton in the U.K. Results from that study were positive with...
NanoVibronix Cites Positive Results from Independent Testing of UroShield
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today cited positive reported outcomes from a study of UroShield® that was conducted at the...
Source: https://incomestatements.info
Category: Stock Reports